Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/02/19 08:18:03」(JST)

wiki en

Lansoprazole (/lænˈsoʊprəzoʊl/ lan-SOH-prə-zohl; INN) is a proton-pump inhibitor (PPI) which inhibits the stomach's production of gastric acids. It is manufactured by a number of companies worldwide under several brand names. In the United States it was first approved by the Food and Drug Administration (FDA) in 1995.^[1] Prevacid patent protection expired on November 10, 2009.^[2]^[3] Since 2009 Lansoprazole has been available over the counter (OTC) in the U.S. in a 15 mg dose marketed by Novartis as Prevacid 24HR.^[4]^[5]^[6] In Australia, it is marketed by Pfizer as Zoton.

Lansoprazole is a proton-pump inhibitor (PPI) in the same pharmacologic class as omeprazole. Lansoprazole has been marketed for many years and is one of several PPIs available.^[7] Lansoprazole is a racemate 1:1-mixture of the enantiomers dexlansoprazole (Dexilant, formerly named Kapidex) and levolansoprazole.^[8] Dexlansoprazole is an enantiomerically pure active ingredient of a commercial drug as a result of the 'enantiomeric shift'.

Lansoprazole's plasma elimination half-life is not proportional to the duration of the drug's effects to the person (i.e. gastric acid suppression). The mean plasma elimination half-life is 1.5 hours,^[9] and the effects of the drug last for over 24 hours after it has been used for 1 day or more.^[10] Lansoprazole, 30 mg administered nasogastrically, effectively controls intragastric pH and is an alternative to i.v. pantoprazole in patients who are unable to swallow solid dosage formulations.^[11]

Indications[edit]

Lansoprazole is indicated for:

Treatment of ulcers of the stomach and duodenum, and NSAID-induced ulcers.
Adjunctive treatment of Helicobacter pylori infection, alongside antibiotics. Treatment to kill Helicobacter pylori (H. pylori) causing ulcers or other problems involves using two other drugs besides lansoprazole. This treatment is known as "triple therapy", and involves taking twice daily for 10 or 14 days lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg.
Treatment of gastroesophageal reflux disease (GERD) (also known as acid reflux disease).
Treatment of Zollinger-Ellison Syndrome.^[5]

Drug interactions[edit]

Lansoprazole interacts with several other drugs, either due to its own nature or as a proton pump inhibitor.^[12]

PPIs reduce absorption of antifungals (itraconazole and ketoconazole) ^[13] and possibly increase Digoxin in plasma
Increases plasma concentrations of Cilostazol (risk of toxicity)
Lansoprazole possibly interacts with, amongst other drugs:
- sucralfate
- ampicillin
- bisacodyl
- clopidogrel
- delavirdine
- fluvoxamine
- iron salts
- voriconazole
- aminophylline and theophylline
- astemizole

Side effects[edit]

Side effects of proton pump inhibitors in general^[14] and lansoprazole in particular^[15] may include:

Infrequent: dry mouth, insomnia, drowsiness, blurred vision, rash, pruritus
Rarely and very rarely: taste disturbance, liver dysfunction, peripheral oedema, hypersensitivity reactions (including bronchospasm, urinary, angioedema, anaphylaxis), photosensitivity, fever, sweating, depression, interstitial nephritis, blood disorders (including leukopenia, leukocytosis, pancytopenia, thrombocytopenia), arthralgia, myalgia, skin reactions^[16] including (erythroderma^[17] Stevens–Johnson syndrome, toxic epidermal necrolysis, bullous eruption)
Severe: Gastro-intestinal disturbances (such as nausea 1.3%, abdominal pain 2.1%, diarrhea 3.8%).^[9]

Proton-pump inhibitors may be associated with a greater risk of hip fractures^[18] and Clostridium difficile-associated diarrhea.^[19] Antacid preparations such as lansoprazole by suppressing acid mediated break down of proteins, leads to an elevated risk of developing food and drug allergies. This happens due to undigested proteins then passing into the gastrointestinal tract where sensitisation occurs. It is unclear whether this risk occurs with only long-term use or with short-term use as well.^[20] Patients are frequently administered the drugs in intensive care as a protective measure against ulcers, but this use is also associated with a 30% increase in occurrence of pneumonia.^[21]

Brand names[edit]

Prevacid 30 mg

Lansoprazole is available as a generic drug in the US, Russian Federation, UK, Canada, Belgium, Finland,^[22] France, Colombia, Italy, Sweden,^[23] and Mexico.^{[citation needed]}

The drug is also sold under several brand names, including:^[1]

Agopton (Germany)
Digest (Indonesia)
Duogast (Syria)
GERD (Pakistan)
Gastrolan (Indonesia)
Gastrovex (Malaysia)
Lanciprol (Greece)
Lansazol (Jordan)
Lansobene (Austria)
Lansoloc (South Africa)
Lansoprazol (Denmark)
Lansoptol (Hungary)
Lansor (Turkey)
Lansox (Italy)
Lanston LFDT (South Korea)
Lenzo (India)
Lanzol (India, Ireland)
Lanzopran (Australia)
Lanzotec (Jordan)
Lanzul (Romania/Slovenia)
Lanton (Israel)
Lantrea (Poland)
Lanzap (Romania)
Lanzo (Sweden)
Lanzopral (Argentina, Chile, Peru, Venezuela [2])
Lanzor (France, South Africa)
Lanzostad (Lithuania, Latvia, Estonia)
Laprazol (Greece)
Levant (Romania)
Limpidex (Italy)
Monolitum (Spain)
Ogast and OgastORO (France)
Ogastro (Mexico)
Prevacid (US. and Canada)
Prevacid 24HR(US)
Prosogan and Prosogan FD (Indonesia)
pro-ulco (Spain)
Refluxon (Hungary)
Sabax (Serbia)
SOLOX (New Zealand)
Takepron (Japan)
Zolt (Finland)
Zoton (Italy, Ireland, Australia, UK)
ZOMEL (Ireland)

References[edit]

^ ^a ^b Mosby's Drug Consult: Lansoprazole
^ Prevacid drug patents
^ Teva to release Prevacid version when patent expires
^ "Novartis launches Prevacid 24HR over-the-counter for full 24-hour frequent heartburn treatment" (PDF) (Press release). November 12, 2009. Retrieved November 13, 2009.
^ ^a ^b "Prevacid 24HR Patient Package Insert" (PDF). November 12, 2009. Retrieved November 13, 2009.
^ "Novartis launches Prevacid 24HR over-the-counter for full 24-hour frequent heartburn treatment" (Press release). November 12, 2009. Retrieved November 13, 2009.
^ http://www.patient.co.uk/showdoc/30002943/
^ http://www.mainecarepdl.org/index.pl/genpharmfiles/memos-and-mailings/pharmacy-benefit-update-summer-fall-2009.pdf^{[dead link]}
^ ^a ^b "Prevacid Pharmacology, Pharmacokinetics, Studies, Metabolism". RxList.com. 2007. Retrieved April 14, 2007.
^ "Prevacid 24HR Fact Sheet" (PDF). November 12, 2009. Retrieved November 13, 2009.
^ Effects on 24-Hour Intragastric pHFreston M.D., Ph.D., James; Yi-Lin Chiu, Ph.D., Wei-Jian Pan, Ph.D., Nancy Lukasik, B.S.N., and Jörg Täubel, M.D., A.F.P.M. (2001). "Effects on 24-Hour Intragastric pH: A Comparison of Lansoprazole Administered Nasogastrically in Apple Juice and Pantoprazole Administered Intravenously". American Journal of Gastroenterology 96 (7): 2058–2065. doi:10.1111/j.1572-0241.2001.03939.x . ISSN 0002-9270. OCLC 440925790. PMID 11467632. Cite uses deprecated parameters (help)
^ British National Formulary (Free registration required) Lansoprazole interactions
^ Antimicrob Agents Chemother. 1991 September; 35(9): 1765–1771. Effects of ranitidine and sucralfate on ketoconazole bioavailability. S C Piscitelli, T F Goss, J H Wilton, D T D'Andrea, H Goldstein, and J J Schentag [1]
^ British National Formulary (Free registration required) 1.3.5 Proton pump inhibitors
^ British National Formulary (Free registration required) Lansoprazole
^ K C Singhal & S Z Rahman, Lansoprazole Induced Adverse Effects on the Skin, Indian Medical Gazette, July 2001, Vol. CXXXV. N0. 7: 223-225
^ Sterry W, Assaf C (2007). "Erythroderma". In Bolognia JL. Dermatology. St. Louis: Mosby. p. 154. ISBN 1-4160-2999-0. .
^ Yang YX, Lewis JD, Epstein S, Metz DC (December 2006). "Long-term proton pump inhibitor therapy and risk of hip fracture". JAMA 296 (24): 2947–53. doi:10.1001/jama.296.24.2947 . PMID 17190895.
^ "Proton pump inhibitors and Clostridium difficile". Bandolier. 2003. Retrieved July 13, 2007.
^ Pali-Schöll I, Jensen-Jarolim E (April 2011). "Anti-acid medication as a risk factor for food allergy". Allergy 66 (4): 469–77. doi:10.1111/j.1398-9995.2010.02511.x . PMID 21121928.
^ Herzig SJ, Howell MD, Ngo LH, Marcantonio ER (May 2009). "Acid-suppressive medication use and the risk for hospital-acquired pneumonia". JAMA 301 (20): 2120–8. doi:10.1001/jama.2009.722 . PMID 19470989.
^ "Vastaavat tuotteet - hintavertailu" (in Finnish).
^ "FASS.se, accessed 2010-02-13" (in Swedish).

External links[edit]

Prevacid official website Takeda Pharmaceuticals North America
Prevacid 24HR official website Novartis Consumer Health
Prevpac official website Takeda Pharmaceuticals North America
U.S. National Library of Medicine: Drug Information Portal - Lansoprazole

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 非ステロイド性抗炎症剤（NSAIDs）（アスピリンを含む）：胃十二指腸障害の一次予防 nsaids including aspirin primary prevention of gastroduodenal toxicity
2. 酸関連疾患治療のためのプロトンポンプ阻害剤の概要および比較 overview and comparison of the proton pump inhibitors for the treatment of acid related disorders
3. 小児および思春期における胃食道逆流症のマネージメント management of gastroesophageal reflux disease in children and adolescents
4. 成人における胃食道逆流症の内科的マネージメント medical management of gastroesophageal reflux disease in adults
5. ヘリコバクターピロリ菌の治療レジメン treatment regimens for helicobacter pylori

English Journal

Relaxant effect of proton pump inhibitors on in vitro myometrium from pregnant women.

Terranova C1, Petrella C2, Improta G3, Severini C4, Signore F5, Damiani P5, Plotti F1, Scarpignato C6, Angioli R1.Author information 1Department of Obstetrics and Gynaecology, "Campus Bio Medico" University, Rome, Italy.2Department of Physiology and Pharmacology "V. Erspamer", Sapienza University, Rome, Italy. Electronic address: carla.petrella@uniroma1.it.3Department of Physiology and Pharmacology "V. Erspamer", Sapienza University, Rome, Italy.4Institute of Cellular Biology and Neurobiology, CNR, Rome, Italy.5Department of Obstetrics and Gynaecology, San Camillo - Forlanini Hospital, Rome, Italy.6Division of Gastroenterology, Department of Clinical Sciences, University of Parma, Italy.AbstractAIM: In this study we investigate in in vitro myometrial tissue samples of pregnant women: (a) the effects of proton pomp inhibitors (PPIs) (omeprazole, esomeprazole, pantoprazole, lansoprazole and rabeprazole) on spontaneous contractions; (b) the muscle-relaxant efficacy of the most active PPI considered (pantoprazole) in comparison with that of other known tocolytics (nifedipine, atosiban, MgSO4, isoxsuprine); (c) the effect of pantoprazole on contractions induced by calcium (Ca(++)), KCl, oxytocin and prostaglandin (PGE2); (d) the possible mediators of pantoprazole relaxant effect.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.Eur J Pharm Sci.2014 Feb 14;52:125-31. doi: 10.1016/j.ejps.2013.10.007. Epub 2013 Nov 9.
AIM: In this study we investigate in in vitro myometrial tissue samples of pregnant women: (a) the effects of proton pomp inhibitors (PPIs) (omeprazole, esomeprazole, pantoprazole, lansoprazole and rabeprazole) on spontaneous contractions; (b) the muscle-relaxant efficacy of the most active PPI cons
PMID 24215738

The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects.

Ding Y, Jia Y, Song Y, Lu C, Li Y, Chen M, Wang M, Wen A.Author information Department of Pharmacy, Xijing Hospital of the Fourth Military Medical University, Xi'an, Shaanxi, China.AbstractPURPOSE: Gastro-esophageal reflux disease is common in patients with type 2 diabetes. A common treatment is the co-administration of proton-pump inhibitors (PPIs) and metformin. To date, however, the effects of co-administration of PPIs, which inhibit organic cation transporter (OCT) activity, on the action of metformin (a well-known substrate of OCTs) have not been clearly demonstrated.
European journal of clinical pharmacology.Eur J Clin Pharmacol.2014 Feb;70(2):141-6. doi: 10.1007/s00228-013-1604-7. Epub 2013 Oct 30.
PURPOSE: Gastro-esophageal reflux disease is common in patients with type 2 diabetes. A common treatment is the co-administration of proton-pump inhibitors (PPIs) and metformin. To date, however, the effects of co-administration of PPIs, which inhibit organic cation transporter (OCT) activity, on th
PMID 24170325

Effect of Proton Pump Inhibitors on In Vitro Activity of Tigecycline against Several Common Clinical Pathogens.

Ni W1, Cai X1, Liang B2, Cai Y2, Cui J1, Wang R2.Author information 1Department of Respiratory Diseases, Chinese People's Liberation Army General Hospital, Beijing, China.2Department of Clinical Pharmacology, Chinese People's Liberation Army General Hospital, Beijing, China.AbstractIn this study, we evaluated the effect of proton pump inhibitors (PPIs) on in vitro antimicrobial activity of tigecycline against several species of clinical pathogens. Clinical non-duplicate isolates of Acinetobacter baumannii, Staphylococcus aureus, Enterococcus faecalis and three species of Enterobacteriaceae (Escherichia coli, Klebsiella pneumonia and Enterobacter cloacae) were collected from a tertiary hospital and their MICs of tigecycline alone and in combination with PPIs (omeprazole, lansoprazole and pantoprazole) were determined. With one randomly selected isolate of each bacterial species, an in vitro time-kill study was performed for the confirmation of the effect of PPIs on tigecycline activity. The MIC changes after PPIs addition correlated with the PPIs concentrations in the test media. Compared with tigecycline alone, the addition of 5 mg/L PPIs could increase the MICs of tigecycline by 0 to 2-fold and the addition of 50 mg/L PPIs could increase the MICs of tigecycline by 4 to >128-fold. The time-kill study confirmed that the addition of PPIs could affect the in vitro activity of tigecycline. Even at low concentration (5 mg/L) of omeprazole and pantoprazole, antagonistic effect could be observed in E. cloacae and E. faecalis strains. We conclude that In vitro activity of tigecycline can be influenced by the presence of PPIs in a concentration-dependent manner.
PloS one.PLoS One.2014 Jan 21;9(1):e86715. doi: 10.1371/journal.pone.0086715. eCollection 2014.
In this study, we evaluated the effect of proton pump inhibitors (PPIs) on in vitro antimicrobial activity of tigecycline against several species of clinical pathogens. Clinical non-duplicate isolates of Acinetobacter baumannii, Staphylococcus aureus, Enterococcus faecalis and three species of Enter
PMID 24466210

Related Pictures

Prevacid Uses, Dosage & Side Effects MedConnections Forums • PREVACID Dosage 24 Hour Prevacid only $14.99 » CIA Coupon PREVACID (lansoprazole) 15mg, 30mg delayed Prevacid 24 HR - FDA prescribing بريفاسيد Prevacid -أدوية Prevacid 24 Hour Coupons | Heartburn

★リンクテーブル★

リンク元	「ランソプラゾール」

「ランソプラゾール」

Lansoprazole
Systematic (IUPAC) name
	(RS)-2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole
Clinical data
Trade names	Prevacid
AHFS/Drugs.com	monograph
MedlinePlus	a695020
Licence data	US FDA:link
Pregnancy cat.	B3 (AU) B (US)
Legal status	POM (UK) OTC (US)
Routes	Oral, IV
Pharmacokinetic data
Bioavailability	80% or more
Protein binding	97%
Metabolism	Hepatic (CYP3A4- and CYP2C19-mediated)
Half-life	1–1.5 hours
Excretion	Renal and fecal
Identifiers
CAS number	103577-45-3
ATC code	A02BC03
PubChem	CID 3883
DrugBank	DB00448
ChemSpider	3746
UNII	0K5C5T2QPG
KEGG	D00355
ChEBI	CHEBI:6375
ChEMBL	CHEMBL480
Chemical data
Formula	C16H14F3N3O2S
Mol. mass	369.363 g/mol
	SMILES FC(F)(F)COc1c(c(ncc1)CS(=O)c3nc2ccccc2n3)C;
	InChI InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22) ; Key:MJIHNNLFOKEZEW-UHFFFAOYSA-N ;
(what is this?) (verify)

　　[★]

英: lansoprazole
商: スタンゾーム、タイプロトン、タケプロン、タピゾール、ラソプラン、ランサップ、ランソラール、ランピオンパック、Prevacid
関: 消化性潰瘍用剤

消化性潰瘍治療薬

攻撃因子抑制剤

プロトンポンプ阻害薬

[Mosby.27s-1] Mosby's Drug Consult: Lansoprazole

[2] Prevacid drug patents

[Teva-3] Teva to release Prevacid version when patent expires

[4] "Novartis launches Prevacid 24HR over-the-counter for full 24-hour frequent heartburn treatment" (PDF) (Press release). November 12, 2009. Retrieved November 13, 2009.

[prevacid24hr-5] "Prevacid 24HR Patient Package Insert" (PDF). November 12, 2009. Retrieved November 13, 2009.

[6] "Novartis launches Prevacid 24HR over-the-counter for full 24-hour frequent heartburn treatment" (Press release). November 12, 2009. Retrieved November 13, 2009.

[7] ttp://www.patient.co.uk/showdoc/30002943/

[8] ttp://www.mainecarepdl.org/index.pl/genpharmfiles/memos-and-mailings/pharmacy-benefit-update-summer-fall-2009.pdf^{[dead link]}

[RxList-9] "Prevacid Pharmacology, Pharmacokinetics, Studies, Metabolism". RxList.com. 2007. Retrieved April 14, 2007.

[10] "Prevacid 24HR Fact Sheet" (PDF). November 12, 2009. Retrieved November 13, 2009.

[11] Effects on 24-Hour Intragastric pHFreston M.D., Ph.D., James; Yi-Lin Chiu, Ph.D., Wei-Jian Pan, Ph.D., Nancy Lukasik, B.S.N., and Jörg Täubel, M.D., A.F.P.M. (2001). "Effects on 24-Hour Intragastric pH: A Comparison of Lansoprazole Administered Nasogastrically in Apple Juice and Pantoprazole Administered Intravenously". American Journal of Gastroenterology 96 (7): 2058–2065. doi:10.1111/j.1572-0241.2001.03939.x . ISSN 0002-9270. OCLC 440925790. PMID 11467632. Cite uses deprecated parameters (help)

[12] British National Formulary (Free registration required) Lansoprazole interactions

[13] Antimicrob Agents Chemother. 1991 September; 35(9): 1765–1771. Effects of ranitidine and sucralfate on ketoconazole bioavailability. S C Piscitelli, T F Goss, J H Wilton, D T D'Andrea, H Goldstein, and J J Schentag [1]

[14] British National Formulary (Free registration required) 1.3.5 Proton pump inhibitors

[15] British National Formulary (Free registration required) Lansoprazole

[16] K C Singhal & S Z Rahman, Lansoprazole Induced Adverse Effects on the Skin, Indian Medical Gazette, July 2001, Vol. CXXXV. N0. 7: 223-225

[bolognia-17] Sterry W, Assaf C (2007). "Erythroderma". In Bolognia JL. Dermatology. St. Louis: Mosby. p. 154. ISBN 1-4160-2999-0. .

[JAMA-18] Yang YX, Lewis JD, Epstein S, Metz DC (December 2006). "Long-term proton pump inhibitor therapy and risk of hip fracture". JAMA 296 (24): 2947–53. doi:10.1001/jama.296.24.2947 . PMID 17190895.

[Bandolier-19] "Proton pump inhibitors and Clostridium difficile". Bandolier. 2003. Retrieved July 13, 2007.

[pmid21121928-20] Pali-Schöll I, Jensen-Jarolim E (April 2011). "Anti-acid medication as a risk factor for food allergy". Allergy 66 (4): 469–77. doi:10.1111/j.1398-9995.2010.02511.x . PMID 21121928.

[JAMA2-21] Herzig SJ, Howell MD, Ngo LH, Marcantonio ER (May 2009). "Acid-suppressive medication use and the risk for hospital-acquired pneumonia". JAMA 301 (20): 2120–8. doi:10.1001/jama.2009.722 . PMID 19470989.

[22] "Vastaavat tuotteet - hintavertailu" (in Finnish).

[23] "FASS.se, accessed 2010-02-13" (in Swedish).

匿名

検索

案内

案内

Prevacid